Sodium Phenylbutyrate Powder, 250 Grams, Rx Only, packaged in 500 cc HDPE bottles and 53 mm CRC c...
FDA Drug Recall #D-0898-2021 — Class II — September 21, 2021
Recall Summary
| Recall Number | D-0898-2021 |
| Classification | Class II — Moderate risk |
| Date Initiated | September 21, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | SigmaPharm Laboratories LLC |
| Location | Bensalem, PA |
| Product Type | Drugs |
| Quantity | 1192 bottles |
Product Description
Sodium Phenylbutyrate Powder, 250 Grams, Rx Only, packaged in 500 cc HDPE bottles and 53 mm CRC caps packed in a carton and then in case packs containing 2 bottles. Sigmapharm Laboratories, LLC, Bensalem, PA 19020, NDC 42794-086-14
Reason for Recall
Failed Impurities/Degradation Specifications; Out of Specification impurity results obtained during routine testing.
Distribution Pattern
Nationwide
Lot / Code Information
Lots 2005401, 2005501, 2005601, 2005701, Exp FEB 2023; Lots 2101401, 2101501, Exp FEB-2024
Other Recalls from SigmaPharm Laboratories LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0766-2021 | Class II | Sodium Phenylbutyrate POWDER, 250 grams bottle,... | Aug 13, 2021 |
| D-0379-2021 | Class III | Asenapine Sublingual Tablets, 5 mg, Rx Only, 60... | Apr 19, 2021 |
| D-0380-2021 | Class III | Asenapine Sublingual Tablets, 10 mg, Rx only, 6... | Apr 19, 2021 |
| D-1344-2014 | Class II | Liothyronine Sodium Tablets, USP 5 mcg, Rx Only... | Apr 22, 2014 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.